Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.

NCT06102343 | Unknown

• 1 other identifier: ALM-HAR-CLS-23-01
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 1

Brief Summary

The ClearSkin module, Er: Glass 1540nm, is largely used in the treatment of acne vulgaris and acne scars. The non-ablative ER:Glass 1540 nm laser deeply penetrates the skin, causing thermal damage to the sebaceous glands, destroying P. acnes bacteria and reducing sebum production, while leaving the epidermis intact. The integrated vacuum mechanism extracts accumulated sebaceous material from the pores, while contact cooling protects the skin, reducing pain and allowing for safer and more effective treatment of the sebaceous glands within the dermis. Based on this background, the investigators have considered a pilot study aimed at assessing the efficacy and safety of the ClearSkin Module in treating subjects with facial acne scars.

Conditions

Acne Scars - Mixed Atrophic and Hypertrophic

Outcome Measures

Primary Outcomes (1)

• Reduction of at least 6 points in Goodman Baron's score at 3-month follow-up visit compared to baseline.

  comparison of acne scars' Goodman Baron's score at baseline with acne scars' Goodman Baron's score at 3-month follow-up visit compared to baseline.

  throughout the study, up to 1 year.

Secondary Outcomes (6)

• Improvement in the treated facial acne scars after ClearSkin according to the General Aesthetic Improvement Scale (GAIS), at the 3-month follow-up visit compared to baseline.

  throughout the study, up to 1 year.

• Improvement in the treated facial acne scars after ClearSkin according to the General Aesthetic Improvement Scale (GAIS), at the 1-month follow-up visit compared to baseline.

  throughout the study, up to 1 year.

• Improvement in skin texture of the treated facial acne scars.

  throughout the study, up to 1 year.

• Participant's satisfaction rates

  throughout the study, up to 1 year.

• Adverse Events frequency & intensity.

  throughout the study, up to 1 year.

Study Arms (1)

acne scars treatment using the Alma Harmony platform with the ClearSkin applicator.

EXPERIMENTAL

treatment of acne scars using the ClearSkin non-ablative ER:Glass 1540nm laser Module.

Device: Alma Harmony

Interventions

Alma Harmony DEVICE

Acne scars treatment using non-ablative ER:Glass 1540 nm laser module.

Also known as: ClearSkin applicator

acne scars treatment using the Alma Harmony platform with the ClearSkin applicator.

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Men or women aged 18 to 50 years
• Presence of mild to moderate facial acne scars (according to Goodman \& Baron's scale)
• Subjects in reasonably good general health, according to the Investigator's judgment;
• Subjects who agree to avoid tanning during the entire investigational period;
• Subjects who agree to avoid any other facial procedure during the entire investigational period; including but not limited to: injectables or threads, peeling of any kind, dermabrasion, facial hair removal, or application of any cosmeceutical/pharmaceutical without the consent from the PI only.
• Subjects able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and comply with the requirements of the entire investigation (ability to attend all the planned investigation visits according to the time limits included) based on Investigator's judgment.
• Subjects willing to sign an informed consent, consent to use their photos for future scientific or marketing purposes, according to the sponsor's needs.

You may not qualify if:

• Subjects with active infections
• Subjects with a history of keloid scarring or hypertrophic scar formation
• Subjects with previous medical treatment of the area, or oral retinoid drug prescribed within the past six months
• Subjects who have been tanning within the past 30 days;
• Previous surgical treatment of the area selected for the treatment with the investigational device;
• Subjects with any inflammatory skin condition e.g., eczema, active herpes simplex, etc. at the treatment site;
• Subjects with the presence of tattoos at the treatment site
• Subjects with skin cancer or any other cancer and/or any cancer drug therapy (such as ducabaxine, fluorouracil, methotrexate, etc.)
• Subjects with history of autoimmune disorder or evidence of immunosuppression;
• Subjects with collagen vascular diseases
• Subjects with thrombocytopenia
• Subjects with peripheral vascular disease
• Subjects with Melasma
• Pregnant or lactating subjects

Sponsors & Collaborators

• Alma Lasers: lead

Study Sites (1)

Up Clinic

Lisbon, 1400-020, Portugal

Location

MeSH Terms

Conditions

Hypertrophy

Condition Hierarchy (Ancestors)

Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Tiago Baptista, MD

  Head of Up Clinic, Lisbon, Portugal

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Natalie Dror, PhD

CONTACT

+972528264282; natalie.dror@almalasers.co.il

Shir Beckerman, MA

CONTACT

+972522906172; shir.beckerman@almalasers.co.il

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 18, 2023
• First Posted: October 26, 2023
• Study Start: January 1, 2024
• Primary Completion: January 1, 2025
• Study Completion: January 1, 2025
• Last Updated: October 26, 2023

Record last verified: 2023-10

Locations

PT (1)